Corvus Pharmaceuticals (CRVS) stock, explained like you're 5

Is Corvus Pharmaceuticals a small, medium or large cap company?

No. Corvus Pharmaceuticals is a small cap stock, not a large cap. Its market cap, which is the total value of all its shares, is about 885 million dollars.

Here is how you can tell. Multiply the share price by the number of shares to get the market cap, then compare it to the usual sizes. Micro cap is under 300 million dollars, small cap is 300 million to 2 billion, mid cap is 2 to 10 billion, large cap is 10 billion and up, and mega cap is over 200 billion. Market caps move every day with the share price, so treat the number as a recent snapshot.

How Corvus Pharmaceuticals makes money

• Selling medicines, medical devices or healthcare services.
• Insurance premiums or hospital and clinic fees.
• Research and licensing deals.

What moves CRVS stock

• Results from clinical trials and approvals from regulators.
• Drug prices, insurance rules and government policy.
• Patents running out and new competing treatments.

In the news lately

• (CRVS) and the Role of Price Sensitive Allocations (Stock Traders Daily)
• Corvus Pharmaceuticals Inc (C17.HA) stock historical prices and data (Yahoo Finance UK)
• Corvus Eczema Trial Is Expected to Enroll About 200 Patients (Stock Titan)
• CRVS Stock Surges 10%, Hits 50 DMA For First Time In A Month Here’s Why Goldman Sachs Sees A 166% Upside (Stocktwits)
• Corvus Stock: Soquelitinib Q1 Interim Futility Analysis AD Drug Advancement (NASDAQ:CRVS) (Seeking Alpha)

Key terms to know before you follow CRVS

• Market cap
• P/E ratio
• EPS (earnings per share)
• Earnings report
• Volatility